Restoring circadian NAD+ oscillations via timed NMN dosing and SIRT1 activation re-synchronizes tissue clocks, reduces p53 acetylation, and clears senescent cells

Hypothesis Aging dampens the 24‑hour NAD+ rhythm, which weakens SIRT1‑mediated deacetylation of core clock proteins and of the senescence regulator p53. When NAD+ oscillations are low, p53 stays acetylated, promotes transcription of SASP factors, and impairs autophagic clearance. Delivering NMN at the phase when NAMPT transcription peaks (subjective morning) together with a low‑dose SIRT1 activator will reinstate NAD+ amplitude, boost SIRT1 activity toward both BMAL1/PER2 and p53, thereby restoring clock precision and removing senescent cells.

Mechanistic rationale

1. CLOCK:BMAL1 drives rhythmic NAMPT expression, setting the tempo for NAD+ synthesis [1].
2. SIRT1 deacetylates BMAL1 and PER2 to sustain oscillation amplitude; low NAD+ reduces this brake, flattening circadian gene expression [2][3].
3. NAMPT inhibition disrupts BMAL1 repression, showing that NAD+ flux is necessary for clock robustness [4].
4. In liver, SIRT1 loss raises NAMPT and NAD+ but uncouples the clock, indicating that SIRT1’s clock‑protective role depends on its deacetylase activity rather than NAD+ levels alone [5].
5. Restoring NAD+/NADH redox balance rejuvenates senescent human mesenchymal stem cells, linking redox state to senescence reversal [6].
6. Acetylated p53 is transcriptionally active for SASP; SIRT1 deacetylates p53, suppressing its pro‑aging program. Thus, NAD+ oscillations gate SIRT1’s dual action on clock and p53.

Predictions

• Participants receiving circadian‑timed NMN plus SIRT1 activator will show a ≥20 % increase in BMAL1/PER2 mRNA oscillation amplitude in peripheral blood monocytes after 4 weeks, whereas a control group receiving the same total NMN dose split across the day will not.
• NAD+ peak‑to‑trough difference will rise proportionally, confirming restored rhythm.
• Concurrently, p53 acetylation levels in the same cells will drop by ≥15 %, SASP cytokines (IL‑6, IL‑8) will decline, and autophagic flux markers (LC3‑II/I ratio, p62 degradation) will improve.
• If the hypothesis is false, baseline NAD+ will rise without amplitude gains, p53 acetylation will stay high, and senescent markers will be unchanged, demonstrating that merely boosting NAD+ pools does not repair clock-driven senescence.

Experimental design (falsifiable test)

• Recruit 60 adults aged 65‑80, randomize to three arms: (A) timed NMN (morning) + low‑dose SIRT1 activator, (B) same total NMN given in three equal doses across 24 h + activator, (C) placebo.
• Collect blood every 4 h over 24 h at baseline and after intervention.
• Measure NAD+ levels (LC‑MS), BMAL1/PER2 mRNA (qPCR), p53 acetylation (immunoprecipitation‑Western), SASP panel (ELISA), autophagy markers.
• Primary outcome: change in oscillation amplitude (cosinor analysis) of BMAL1/PER2. Secondary outcomes: NAD+ rhythm, p53 acetylation, SASP, autophagy.

Why this extends prior work Existing NMN/NR trials report only static NAD+ increases and functional endpoints without addressing circadian dynamics. By targeting the oscillatory component, we test whether the clock’s temporal coherence—not just NAD+ abundance—is the limiting geroprotective lever. Failure to improve amplitude despite NAD+ elevation would falsify the claim that circadian restoration is the primary anti‑aging mechanism, pushing focus toward downstream effectors such as p53 deacetylation or tissue‑specific SIRT1 isoforms.